Commercialisation5 Feb 2019 17:00
Looking at Merck's antimicrobial web pages, I see they took over a company called Cubist in 2014 …
According to Wiki,
Cubist Pharmaceuticals was a U.S. biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products. Its main products target pathogens like MRSA.
Cubist was one of the few firms that continued to research in antibiotics while larger pharmaceutical companies have abandoned such research.[1] The company employs 638 people, with 370 in their headquarters in Lexington, MA.[2] As of 2011, the company’s headquarters are under expansion and is expected to occupy 373,000 sq ft (34,700 m2) in Lexington, MA. On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion) as entree to the market for drugs that can combat superbugs.